Overview

* Rani announced $1.085 bln collaboration with Chugai for oral therapy development

* Completed $60.3 mln oversubscribed private placement, extending cash runway into 2028

* Net loss for Q3 2025 decreases to $7.9 mln from $12.7 mln in Q3 2024

Outlook

* Rani plans to initiate Phase 1 trial for RT-114 by end of 2025

* Company expects cash runway to extend into 2028

Result Drivers

* OVERSUBSCRIBED PRIVATE PLACEMENT - $60.3 mln private placement led by Samsara BioCapital supports financial stability

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Net -$7.91

Income mln

Q3 $7.26

Operatin mln

g

Expenses

Q3 -$7.26

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Rani Therapeutics Holdings Inc ( RANI ) is $10.50, about 76.2% above its November 5 closing price of $2.50

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)